Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (8415)	11/8/2000 8:12:15 PM
From: sim1	Respond to of 9719

Genzyme Transgenics to Replay Web Cast FRAMINGHAM, Mass., Nov. 8 /PRNewswire/ -- Genzyme Transgenics (Nasdaq: GZTC - news) held a conference call today to discuss plans to reacquire rights to rhATIII from Genzyme General. As part of the Company's ongoing efforts to ensure full disclosure to all parties, a live webcast was arranged. Due to a technical difficulty at the webcast provider, many participants were not able to access the live webcast. However, the Company is making a replay of the webcast available through its web site. To access this archive, please log onto transgenics.com. Alternatively, the webcast replay may be accessed by logging on to streetfusion.com. Genzyme Transgenics apologizes for any inconvenience that may have resulted from the failure of the live webcast. Genzyme Transgenics Corporation is a leader in developing medicines from the milk of specially bred animals, primarily goats. Many of the medicines under development are monoclonal antibodies and immunoglobulin fusion proteins. To date, GTC has formed more than a dozen collaboration agreements which provide for production of specific proteins. Additional information is available on GTC's web site, transgenics.com. SOURCE: Genzyme Transgenics Corporation